Oncotarget

Research Papers:

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism

Supriya Shah _, Whitney J. Carriveau, Jinyang Li, Sydney L. Campbell, Piotr K. Kopinski, Hee-Woong Lim, Natalie Daurio, Sophie Trefely, Kyoung-Jae Won, Douglas C. Wallace, Constantinos Koumenis, Anthony Mancuso and Kathryn E. Wellen

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:43713-43730. https://doi.org/10.18632/oncotarget.9666

Metrics: PDF 1506 views  |   HTML 1739 views  |   ?  


Abstract

Supriya Shah1, Whitney J. Carriveau1, Jinyang Li1, Sydney L. Campbell1, Piotr K. Kopinski5,6, Hee-Woong Lim2, Natalie Daurio3, Sophie Trefely1, Kyoung-Jae Won2, Douglas C. Wallace5, Constantinos Koumenis3, Anthony Mancuso1,4, Kathryn E. Wellen1

1Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

2Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

3Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

4Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

5Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA

6Howard Hughes Medical Institute, Philadelphia, PA 19104, USA

Correspondence to:

Kathryn E. Wellen, e-mail: wellenk@exchange.upenn.edu

Keywords: acetyl-CoA, prostate cancer, fatty acid metabolism, AMPK, ER stress

Received: December 22, 2015    Accepted: May 08, 2016    Published: May 27, 2016

ABSTRACT

The androgen receptor (AR) plays a central role in prostate tumor growth. Inappropriate reactivation of the AR after androgen deprivation therapy promotes development of incurable castration-resistant prostate cancer (CRPC). In this study, we provide evidence that metabolic features of prostate cancer cells can be exploited to sensitize CRPC cells to AR antagonism. We identify a feedback loop between ATP-citrate lyase (ACLY)-dependent fatty acid synthesis, AMPK, and the AR in prostate cancer cells that could contribute to therapeutic resistance by maintaining AR levels. When combined with an AR antagonist, ACLY inhibition in CRPC cells promotes energetic stress and AMPK activation, resulting in further suppression of AR levels and target gene expression, inhibition of proliferation, and apoptosis. Supplying exogenous fatty acids can restore energetic homeostasis; however, this rescue does not occur through increased β-oxidation to support mitochondrial ATP production. Instead, concurrent inhibition of ACLY and AR may drive excess ATP consumption as cells attempt to cope with endoplasmic reticulum (ER) stress, which is prevented by fatty acid supplementation. Thus, fatty acid metabolism plays a key role in coordinating ER and energetic homeostasis in CRPC cells, thereby sustaining AR action and promoting proliferation. Consistent with a role for fatty acid metabolism in sustaining AR levels in prostate cancer in vivo, AR mRNA levels in human prostate tumors correlate positively with expression of ACLY and other fatty acid synthesis genes. The ACLY-AMPK-AR network can be exploited to sensitize CRPC cells to AR antagonism, suggesting novel therapeutic opportunities for prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9666